Abstract
Background Most infections of Epstein-Barr virus (EBV), which is potentially neurotropic, occurred in childhood, but little is known about its association with child neurodevelopmental outcomes.
Methods We determined whether EBV seropositivity was associated with parent-reported attention deficit hyperactivity disorder (ADHD), learning disability, or special education utilization among children, using data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004. Potential confounding factors were adjusted using survey logistic regression models.
Results EBV seroprevalence was 69.6% (95% CI, 67.1%-72.1%) for U.S. children aged 6-19. The prevalence was 8.86% (95% CI, 7.47%-10.47%) for ADHD among 6-19 year olds, 11.70% (95% CI, 9.84%-13.87%) for learning disability among 6-15 year olds, and 10.18% (95% CI, 8.58%-12.05%) for special education among 6-17 year olds. Children with positive anti-EBV had higher crude prevalence rates of learning disability and special education but not ADHD compared with those with negative anti-EBV. The adjusted odds ratios were 2.76 (95% CI, 1.53-4.96) for learning disability, 3.58 (95% CI, 1.92-6.55) for special education, and 0.77 (95% CI, 0.42-1.38) for ADHD, when comparing children with positive and negative anti-EBV.
Conclusions EBV seropositivity was associated with learning disability and special education among U.S. children. Future studies that longitudinally examine the associations are warranted.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://wwwn.cdc.gov/nchs/nhanes/Default.aspx
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced are available online at: https://wwwn.cdc.gov/nchs/nhanes/Default.aspx
